Aurora Cannabis (ACB, $5.70) shares drop in pre-market, after analyst downgrade
Shares of Aurora Cannabis fell -4.7% in premarket trading Monday, after a rating downgrade from analyst Stifel Nicolaus .
Stifel Nicolaus lowered his rating on the medical marijuana company’ shares to sell from hold. The analyst also cut his price target to C$5 ($3.78) from C$7 ($5.27.)
Last week, Aurora Cannabis reported quarterly revenue that increased +52% to C$98.9 million ($75 million), but fell short of Wall Street consensus of $78 million. Cannabis sales volumes over the April to June period, nearly doubled from the prior quarter to 17,793 kilograms, but average selling prices dropped -16.8% from the third quarter to C$5.32 per gram on increased supply of lower-yielding recreational marijuana in the domestic market.
ACB in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2024
ACB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 38 cases where ACB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ACB as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on October 01, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
ACB moved below its 50-day moving average on September 03, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACB crossed bearishly below the 50-day moving average on September 09, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ACB entered a downward trend on October 07, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 69%.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.630) is normal, around the industry mean (55.759). P/E Ratio (0.000) is within average values for comparable stocks, (89.250). ACB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.890). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (1.538) is also within normal values, averaging (18.547).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a licensed producer of medical marijuana in Canada
Industry PharmaceuticalsOther